Coatings for medical devices comprising a therapeutic agent and a metallic material

• US 8,815,275 B2
• Filed: 06/28/2006
• Issued: 08/26/2014
• Est. Priority Date: 06/28/2006
• Status: Expired due to Fees

• Current Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Original Assignee: Boston Scientific Scimed, Inc. (Boston Scientific Corporation)
• Inventors: Zhou, Pu
• Primary Examiner(s): Long, Scott
• Assistant Examiner(s): Alawadi, Sarah
• Application Number:
  US11/478,095
• Publication Number:
  US 20080003251A1
• Time in Patent Office: 2,981 Days
• Field of Search: None
• US Class Current: 424/423
• CPC Class Codes: A61F 2/82 Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents stent-grafts for tubular structures of the body other than blood vessels A61F2/04; stent-grafts for blood vessels A61F2/07; instruments specially adapted for placement or removal of stents or stent-grafts A61F2/95; for closing wounds, or holding wounds closed A61B17/04 - A61B17/115; dilators A61M29/00
• CPC Class Codes: A61F 2002/30322 differing in surface structures
• CPC Class Codes: A61F 2250/0026 differing in surface structures
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 31/082 Inorganic materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

The invention relates generally to an implantable medical device for delivering a therapeutic agent to the body tissue of a patient, and a method for making such a medical device. In particular, the invention pertains to an implantable medical device, such as an intravascular stent, having a coating comprising a first coating composition comprising a therapeutic agent and, optionally, a polymer; and a second coating composition comprising a metallic material.

Claims

1. An implantable intravascular stent comprising:

(a) a stent sidewall structure defining a surface; and

(b) a coating comprising

(i) a first coating composition formed of a material selected from the group consisting of one or more therapeutic agents and one or more polymers, the first coating composition contacting at least a portion of the surface of the stent sidewall structure wherein the first coating composition has a first thickness measured from the surface of the stent sidewall structure; and

(ii) a second coating composition comprising a material different from the first coating composition, the second coating composition comprising a metallic material and being substantially free of any polymer, the second coating contacting at least a portion of the surface of the stent sidewall structure, at least a portion of the second coating composition being disposed adjacent to the first coating composition on the surface of the stent sidewall structure, wherein the second coating composition has a second thickness measured from the surface of the stent sidewall structure; and

wherein the second thickness of the second coating composition is the same as or greater than the first thickness of the first coating composition, with the proviso that the second coating composition does not overcoat the first coating composition and at least a portion of the first coating composition remains exposed.

2. The stent of claim 1, wherein the second coating composition is disposed upon less than all of the outer surface of the first coating composition.

3. The stent of claim 1, wherein the surface of the stent sidewall structure is an abluminal surface.

4. The stent of claim 1, wherein the stent sidewall structure comprises a plurality of struts and openings and the surface of the stent sidewall structure is the abluminal surface of the stent.

5. The stent of claim 4, wherein the surface of the stent sidewall structure is the abluminal surface of at least one of the struts.

6. The stent of claim 5, wherein the first coating composition and the second coating composition are disposed upon at least a portion of the adluminal surface of at least one of the struts.

7. The stent of claim 1, wherein the one or more therapeutic agents comprise an agent that inhibits smooth muscle cell proliferation.

8. The stent of claim 1, wherein the one or more therapeutic agents comprise an antithrombogenic agent, anti-angiogenesis agent, anti-proliferative agent, antibiotic, antirestenosis agent, growth factor, immunosuppressant or radiochemical.

9. The stent of claim 1, wherein the one or more therapeutic agents comprise an antirestenosis agent.

10. The stent of claim 1, wherein the one or more therapeutic agents comprise paclitaxel.

11. The stent of claim 1, wherein the one or more therapeutic agents comprise sirolimus, tacrolimus, pimecrolimus, everolimus or zotarolimus.

12. The stent of claim 1, wherein the metallic material is selected from the group consisting of stainless steel, nickel, titanium, chromium and alloys thereof.

13. The stent of claim 1, wherein the one or more polymers are selected from the group consisting of styrene-isobutylene copolymer, polylactic acid, poly(methylmethacrylatebutylacrylate-methylmethacrylate).

14. The stent of claim 1, wherein the first coating composition forms a first layer having a thickness of about 1 to about 30 microns.

15. The stem of claim 1 wherein the second coating composition forms a second layer having a thickness of about 0.1 to about 50 microns.

16. The stent of claim 1, wherein the second thickness of the second coating composition is greater than the first thickness of the first coating composition.

17. The stent of claim 1, wherein the first thickness of the first coating composition is equal to the second thickness of the second coating composition.

18. The stent of claim 1, wherein the first coating comprises at least one therapeutic agent and at least one polymer.

19. The stent of claim 4, wherein the first coating composition and the second coating composition are disposed upon at least a portion of the adluminal surface.

20. The stent of claim 1, wherein the second thickness is relatively greater than the first thickness and the second coating composition of the coating is exposed for contact with a wall of a lumen when the stent is delivered into the lumen, and the first coating composition of the coating has an outer surface substantially restricted from contact with the wall of the lumen when the stent is delivered into the lumen.

21. The stent of claim 20, wherein the second coating composition is disposed upon at least a portion of the outer surface of the first coating composition.

22. The stent of claim 1, with the proviso that no portion of the second coating composition overcoats the first coating composition.